Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TETRACOSACTIDE CRS (20.5 MG)

TETRACOSACTIDE CRS (20.5 MG)

ND

DISCOVER
GOLIMUMAB BRP (25 MG)

GOLIMUMAB BRP (25 MG)

ND

DISCOVER
MONOCLONAL ANTIBODY FOR SYSTEM PERFORMANCE CRS (100 MG)

MONOCLONAL ANTIBODY FOR SYSTEM PERFORMANCE CRS (100 MG)

ND

DISCOVER
URSODEOXYCHOLIC ACID IMPURITYJ CRS (0.016 MG)

URSODEOXYCHOLIC ACID IMPURITYJ CRS (0.016 MG)

ND

DISCOVER
AMLODIPINE FOR SYSTEM SUITABILITY CRS (1.002 MG)

AMLODIPINE FOR SYSTEM SUITABILITY CRS (1.002 MG)

ND

DISCOVER
CLONAZEPAM IMPURITY A CRS (5 MG)

CLONAZEPAM IMPURITY A CRS (5 MG)

ND

DISCOVER
MACROGOL POLY(VINYL ACETATE)-POLY(VINYLCAPROLACTAM) GRAFTED

MACROGOL POLY(VINYL ACETATE)-POLY(VINYLCAPROLACTAM) GRAFTED

ND

DISCOVER
BUTYLHYDROXYTOLUENE FOR ID AND ASSAY CRS (160 MG)

BUTYLHYDROXYTOLUENE FOR ID AND ASSAY CRS (160 MG)

ND

DISCOVER
L-MALIC ACID CRS (15 MG)

L-MALIC ACID CRS (15 MG)

ND

DISCOVER
PALONOSETRON HYDROCHLORIDE CRS (80 MG)

PALONOSETRON HYDROCHLORIDE CRS (80 MG)

ND

DISCOVER
PALONOSETRON FOR SYSTEM SUITABILITY CRS (15 MG)

PALONOSETRON FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
BROMPERIDOL DECANOATE FOR SYSTEM SUITABILITY CRS (15 MG)

BROMPERIDOL DECANOATE FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER